Company Description
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.
The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment.
The company has a collaboration with Merck & Co., Inc. to develop α7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions.
Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
| Country | Australia |
| Founded | 1996 |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Spyridon Papapetropoulos |
Contact Details
Address: 200 Greenhill Road Eastwood, SA 5063 Australia | |
| Phone | 61 8 8150 7400 |
| Website | bionomics.com.au |
Stock Details
| Ticker Symbol | BNOX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $15.45 |
| CIK Code | 0001191070 |
| CUSIP Number | 09063M205 |
| ISIN Number | US09063M2052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President and Director |
| Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer |
| Elizabeth Doolin | Senior Vice President of Clinical Development |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Adrian Hinton BEC, F.C.A. | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 8-K | Current Report |
| Nov 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 8, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 8-K | Current Report |
| Oct 9, 2024 | PRE 14A | Other preliminary proxy statements |